Mechanism of Action: Zoledronic Acid (Zometa)

During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Warren Fingrut, MD, discussed a study looking at HLA antibody burden among patients with blood cancers, particularly women who have carried multiple pregnancies.

In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.

During a Case-Based Roundtable® event, Misako Nagasaka, MD, discussed treatment for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.

During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.